Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs.
- DOI
- 10.1016/j.oraloncology.2026.108125
- Published
- 2026-09-21
- Container
- Oral Oncol
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.oraloncology.2026.108125,
title = {Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs.},
author = {Patel AN and Wu SS and Colevas AD and Divi V.},
year = {2026},
journal = {Oral Oncol},
doi = {10.1016/j.oraloncology.2026.108125},
url = {https://doi.org/10.1016/j.oraloncology.2026.108125}
}RIS
TY - JOUR TI - Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs. AU - Patel AN AU - Wu SS AU - Colevas AD AU - Divi V. PY - 2026 JO - Oral Oncol DO - 10.1016/j.oraloncology.2026.108125 UR - https://doi.org/10.1016/j.oraloncology.2026.108125 ER -
APA
AN, P., SS, W., AD, C., & V., D. (2026). Estimated costs of intravenous vs subcutaneous pembrolizumab in perioperative head and neck cancer: subcutaneous administration is unlikely to reduce costs.. Oral Oncol. https://doi.org/10.1016/j.oraloncology.2026.108125
Source records
- europe-pmc · retrieved 2026-09-27T14:06:39.272Z